Verrica Pharmaceuticals Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

VRCA$3.52-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 202 and

BALANCE SHEETS

(in thousands, except share and per share amounts)

	December 31,
	2025	2024
ASSETS
Current assets:
Cash and cash equivalents	$30,147	$46,329
Accounts receivable	5,260	48
Collaboration revenue, billed and unbilled	137	29
Deferred R&D services, current portion (Note 12)	1,958	—
Inventory	2,236	2,463
Prepaid expenses and other current assets	2,801	2,310
Total current assets	42,539	51,179
Property and equipment, net	209	589
Operating lease right-of-use asset	540	836
Finance lease right-of-use asset	1,113	1,154
Deferred R&D services, non-current portion (Note 12)	2,354	—
Other non-current assets	376	376
Total assets	$47,131	$54,134
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable	$2,072	$1,896
Accrued expenses and other current liabilities	12,837	13,511
Deferred revenue	782	—
Current portion of long-term debt	—	12,938
Operating lease liability	341	315
Finance lease liability	405	352
Total current liabilities	16,437	29,012
Operating lease liability	242	583
Finance lease liability	643	768
Derivative liability	—	2,648
R&D Funding Liability (Note 12)	5,066	—
Long-term debt	—	30,983
Total liabilities	22,388	63,994
Commitments and Contingencies (Note 6)
Stockholders’ (deficit) equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—
Common stock, $0.0001 par value; 200,000,000 authorized; 17,189,300 shares issued and 17,178,786 shares outstanding as of December 31, 2025 and 9,188,513 shares issued and 9,177,999 shares outstanding as of December 31, 2024	2	1
Treasury stock, at cost, 10,514 shares as of December 31, 2025 and December 31, 2024	—	—
Additional paid-in capital	349,654	297,166
Accumulated deficit	(324,913)	(307,027)
Total stockholders’ (deficit) equity	24,743	(9,860)
Total liabilities and stockholders’ (deficit) equity	$47,131	$54,134

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.